Correlation between in vitro and in vivo activity of antifungal agents against yeasts

Journal de Mycologie Medicale

Volumn 6, Issue 3, 1996, Pages 118-122

  Bille, J ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

antifungal agents; in vitro activity; in vitro in vivo correlation; in vivo activity; resistance

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE; POLYENE; PYRROLE;

ANTIFUNGAL ACTIVITY; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; IN VITRO STUDY; MYCOSIS; SHORT SURVEY; YEAST;

EID: 0029848840     PISSN: 11565233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (23)

1. Akova M, Akahn HE, Uzun Ö, Gür D. Emergence of Candida krusei infections after therapy of oropharyngeal candidiasis with fluconazole. Eur J Clin Microbiol Infect Dis 1991;10:598-9.
2. Akova M, Akahn HE, Uzun Ö, Hayran M, Tekuzman G, Kansu E, Aslan S, Telatar H. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. Clin Infect Dis 1994;18:298-304.
3. Anaissie EJ, Karyotakis NC, Hachem R, Dignani MC, Rex JH, Paetznick V. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J Infect Dis 1994; 170:384-9.
4. Bart-Delabesse E, Boiron P, Carlotti A, Dupont B. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol 1993;31:2933-7.
5. Boerlin P, Addo M, Boerlin-Petzold F, Durussel C, Pagani JL, Chave JP, Bille J. Transmission of oral Candida albicans strains between HIV-positive patients. Lancet 1995;345:1052-3.
6. Goff DA, Koletar SL, Buesching WJ, Barnishan J, Fass RJ. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Infect Dis 1995;20:77-83.
7. Le Guennec R, Reynes J, Mallié M, Pujol C, Janbon F, Bastide JM. Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: multilocus enzyme electrophoresis analysis and antifungal susceptibilities. J Clin Microbiol 1995; 33:2732-7.
8. Lynch ME, Sobel JD, Fidel PL Jr. The role of antifungal drug resistance in the pathogenesis of recurrent vulvo-vaginal candidiasis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept. 17-20, 1995. Abstract E-66, p. 97, San Francisco.
9. Meunier F, Aoun M, Gerard M. Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole. Rev Infect Dis 1990; 12:S364-8.
10. Millon L, Manteaux A, Reboux G, Drobacheff C, Monod M, Barale T, Michel-Briand Y. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J Clin Microbiol 1994;32:1115-8.
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard M27-P. National Committee for Clinical Laboratory Standards, Villanova, PA 1992.
12. Pagani JL, Chave JP, Iten A, Durussel C, Bille J, Glauser MP. Treatment of oropharyngeal candidiasis (OPC) resistant to fluconazole (F) with escalating doses. The third Conference on Retrovirus and Opportunistic Infections, Jan 30, 1996. Abstract 569, p. 158, Washington DC.
13. Pfaller MA, Rhine-Chalberg J, Redding SW, Smith J, Farinacci G, Fothergill AW, Rinaldi MG. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994;32:59-64.
14. Price MF, La Rocco MT, Gentry LO. Fluconazole susceptibilites of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother 1994;38:1422-4.
15. Rex JH, Pfaller A, Rinaldi MG, Polak A, Galgiani JN. Antifungal susceptibility testing. Clin Microbiol Rev 1993;6:367-81.
16. Rex JH, Bennet JE, Sugar AM, Pappas PG, Van der Horst CM, Edwards JE et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-30.
17. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
18. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of non neutropenic patients with candidemia. Antimicrob Agents Chemother 1995;39:40-4.
19. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995;39:2378-86.
20. Shadomy S, White SC, Yu HP, Dismukes WE, and the NIAID Mycoses Study Group. Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis 1985;152. 1249-56.
21. Troillet N, Durussel C, Bille J, Glauser MP, Chave JP. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1993;12:911-15.
22. Velez JD, Allendoerfer R, Luther M, Rinaldi MG, Graybull JR. Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis 1993; 168:508-10.
23. Vuffray A, Durussel C, Boerlin P, Boerlin-Petzold F, Bille J, Glauser MP, Chave JP. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 1994;8:708-9.